Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program-Reference-Cited by-同舟云学术

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

Published:2024-01-23 Issue:2 Volume:25 Page:299-314
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

King Brett,Soung Jennifer,Tziotzios Christos,Rudnicka Lidia,Joly Pascal,Gooderham Melinda,Sinclair Rodney,Mesinkovska Natasha A.,Paul Carle,Gong Yankun,Anway Susan D.,Tran Helen,Wolk Robert,Zwillich Samuel H.,Lejeune Alexandre

Funder

Pfizer

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40257-024-00846-3.pdf

Reference43 articles.

1. Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81–9.

2. Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163–70.

3. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008; (2):CD004413.

4. Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675–82.

5. Lauron S, Plasse C, Vaysset M, et al. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(3):281–8.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity;European Journal of Medicinal Chemistry;2024-12

2. Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis;Dermatology and Therapy;2024-09-10

3. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

4. Ritlecitinib in severe alopecia areata: a profile of its use;Drugs & Therapy Perspectives;2024-09

5. CS12192: A novel selective and potent JAK3 inhibitor mitigates acute graft-versus-host disease in bone marrow transplantation;Transplant Immunology;2024-08